NEW YORK – Nektar Therapeutics and Merck on Wednesday announced plans to conduct a clinical trial of Nektar's IL-2 pathway agent bempegaldesleukin combined with pembrolizumab (Merck's Keytruda) as a first-line treatment for certain patients with PD-L1-positive head and neck cancer.